Published Date: 18 Dec 2024
First-of-its-kind research looking at survival rates for patients with incurable larynx cancer has been published.
Read Full NewsMind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]
Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.
Weight-Adjusted Waist Index Can Predict CVD Risk in Cardiovascular Kidney Metabolic Syndrome
1.
A study outlines the need for policies that enhance cancer patients' autonomy and information.
2.
Heavy Cannabis Use Tied to Increased Head and Neck Cancer Risk
3.
Radiation therapy for patients with breast cancer
4.
Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.
5.
No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says
1.
The Predictive Power of Targeted Radionuclide Therapy in Advanced Breast Cancer
2.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
3.
Innovative Strategies in Prostate Cancer Management: From Surveillance to Systemic Therapies
4.
Unlocking the Mystery of Methaemoglobinaemia: A New Hope for Treatment
5.
Cardiotoxicity Beyond Anthracyclines: Redefining Risk in the Cardio-Oncology Era
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part I
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
4.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
5.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation